secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001048477-26-000002
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin Q4 rev $875M (+17% Y/Y); GAAP net loss $47M on ROCTAVIAN withdrawal; Amicus deal on track
--------------------------------------------------------------------------------

- Q4 total revenues $875M (+17% Y/Y); full-year $3.22B (+13% Y/Y).
- Q4 GAAP net loss of $47M vs $125M income prior year; Non-GAAP income $89M vs $180M.
- ROCTAVIAN withdrawal triggered ~$240M Q4 charges ($119M inventory write-off, $118M asset impairments).
- VOXZOGO FY revenue $927M (+26% Y/Y); PALYNZIQ $433M (+22% Y/Y).
- 2026 guidance provided (ex-Amicus); Amicus acquisition expected to close in Q2'26.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847726000002/0001048477-26-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847726000002/bmrn-20260223.htm
  HTML page:      https://secwatch.observer/filing/0001048477-26-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer